Lenaerts, C. (2019). Défis et stratégies novatrices pour la quantification de la marinobufagénine : application au syndrome de prééclampsie. Unpublished doctoral thesis, Université de Mons. Jury: Blankert, B. (Promotor), Duez, P., Carlier, S., Gerbaux, P., ... Colet, J.-M. |
 | Lenaerts, C., Wells, M., Hambye, S., & Blankert, B. (17 January 2019). Marinobufagenin extraction from Rhinella marina toad glands: alternative approaches for a systematized strategy. Journal of Separation Science, 42 (7), 1384 - 1392. doi:10.1002/jssc.201800879  Peer Reviewed verified by ORBi |
Lenaerts, C., Wells, M., Hambye, S., & Blankert, B. (12 September 2018). Quantification of endogenous marinobufagin by a high-specific and very sensitive UPLC-MS/MS assay in non-patological pregnancy and preeclampsia. Paper presented at DA-PBA 2018 : 11th International symposium on Drug Analysis - 29th International Symposium on Pharmaceutical and Biomedical Analysis, Leuven, Belgium. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (17 May 2018). Revealing of endogenous Marinobufagin by an ultra-specific and sensitive UHPLC-MS/MS assay in pregnant women. Talanta, 187, 193-199. Peer Reviewed verified by ORBi |
Laenens, E., Lenaerts, C., & Blankert, B. (2017). Le venin de crapaud buffle au secours des femmes enceintes. LUMONS - élément. |
Wells, M., Lenaerts, C., & Blankert, B. (2017). Amélioration des techniques d'extraction de la marinobufagénine de matrices complexes. Unpublished master thesis, Université de Mons. Jury: . |
| Lenaerts, C., & Blankert, B. (2017). Le venin thérapeutique - Quand le poison devient un remède. |
| Wells, M., Lenaerts, C., Hambye, S., & Blankert, B. (28 March 2017). Stratégies d'extraction et de purification de la Marinobufagénine à partir du venin du crapaud Bufo marinus. Poster session presented at 12ème Congrès de l'Association Francophone des Sciences Séparatives, Paris, France. |
| Lenaerts, C., & Blankert, B. (2017). le venin de crapaud pour diagnostiquer un syndrome préoccupant chez la femme enceinte. |
Blankert, B., & Lenaerts, C. (2017). UMons: vers un diagnostic au venin de crapaud. Groupe Sud Presse. |
| Lenaerts, C., & Blankert, B. (2017). Intérêt des venins dans le diagnostic thérapeutique. |
Wells, M., Lenaerts, C., Hambye, S., & Blankert, B. (17 October 2016). Extraction and purification strategies of marinobufagenin from bufo marinus toad venom. Paper presented at 19th Forum of Pharmaceutical Sciences, Bruxelles, Belgium. |
| Lenaerts, C., Blankert, B., Bond, L., Tuytten, R., Van Antwerpen, P., & Delporte, C. (17 October 2016). Elaboration of a quantification assay of marinobufagenin in human plasma: a novel approach based on response factor quantification by LC-MS/MS. Paper presented at 19th Forum of Pharmaceutical Sciences, Bruxelles, Belgium. |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (15 August 2016). Early prediction of preeclampsia risk assessment: analytical determination for marinobufagenin in pregnant women. Journal of Maternal-Fetal and Neonatal Medicine, 29, 18. Peer Reviewed verified by ORBi |
Lenaerts, C., Tuytten, R., Bond, L., Delporte, C., Van Antwerpen, P., & Blankert, B. (06 July 2016). A LC-MS assay for identification and quantification of marinobufagenin in human: a novel approach for preeclampsia risk evaluation. Paper presented at MASCL, Salzburg, Austria. Peer reviewed |
Wells, M., Lenaerts, C., & Blankert, B. (2016). Exploration et perfectionnement des techniques de purification de la Marinobufagénine à partir du venin de Bufo Marinus. |
Lenaerts, C., Tuytten, R., Bond, L., Delporte, C., Van Antwerpen, P., & Blankert, B. (12 May 2016). Early prediction of preeclampsia risk assessment: analytical determination for marinobufagenin in pregnant women. Paper presented at Second International Congress on Maternal Hemodynamics, Rome, Italy. Peer reviewed |
Lenaerts, C., Tuytten, R., Bond, L., Delporte, C., Van Antwerpen, P., & Blankert, B. (27 January 2016). Setting up of a LC-MS/MS assay for identification and quantification of MBG in pregnant women for preeclampsia risk evaluation. Poster session presented at HTC-14 ; 14th International Symposium on Hyphenated Techniques in Chromatography and Separation Technology, Ghent, Belgium. |
Lenaerts, C., & Blankert, B. (15 October 2015). Marinobufagenin as a promising preeclampsia assessment marker. Paper presented at Séminaire Hôpital Ambroise Paré, Mons, Belgium. |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (24 September 2015). Marinobufagenin as a promising preeclampsia risk assessment marker: purification from toad venom and LC-MS identification in human plasma. Paper presented at ISSHP (International Society for the Study of Hypertension in Pregnancy) 2015, Budapest, Hungary. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (13 July 2015). Marinobufagenin as a potential biomarker for preeclampsia risk assessment: purification from Bufo Marinus toad venom as support for a human plasma LC-MS/MS assay. Paper presented at Joint meeting of the GP-TCM Research Association, the TCM Chemistry Specialty Committee and the TCM Pharmaceutical Analysis Specialty Committee of the World Federation of Chinese Medicine Societies, Mons, Belgium. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (09 July 2015). Marinobufagenin as a promising preeclampsia risk assessment marker: purification from toad venom and LC-MS identification in human plasma. Pregnancy Hypertension, 5 (3), 213-214. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (15 May 2015). Marinobufagenin : extraction and LC-MS/MS identification in toad venom and human plasma as a promising preeclampsia risk stratification tool. Poster session presented at Bioforum 2015- ULG, Liège, Belgium. |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (15 May 2015). LC-MS/MS analysis of marinobufagenin in human plasma : an encouraging predictive tool for preeclampsia risk stratification. Paper presented at Forum SBSP 2015, Blankenberge, Belgium. |
| Bond, L., Nolan, C., Hyland, K., Lenaerts, C., Baker, P., Kenny, L., & Tuytten, R. (26 October 2014). PREECLAMPSIA RISK STRATIFICATION EARLY IN PREGNANCY: LEVERAGING A PROMISING METABOLOMICS DISCOVERY INTO A LC-MS BASED CLINICAL ASSAY. Poster session presented at ISSHP (International Society of the Study of Hypertension in Pregnancy) World Congress, New Orleans, United States - Louisiana. |
| Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (17 October 2014). Analysis of marinobufagenin in plasma for preeclampsia risk assessment: a promising early predictive tool. Paper presented at 1st International Congress on Maternal Hemodynamics, Hasselt, Belgium. Peer reviewed |
| Bond, L., Lenaerts, C., Benton, C., Baker, P., Kenny, L., & Tuytten, R. (04 September 2014). Preeclampsia risk stratification early in pregnancy: Conversion of a promising metabolomics discovery into a LC-MS based clinical assay. Poster session presented at MSACL, Salzburg, Austria. |
| Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (03 September 2014). Identification of marinobufagenin in plasma as a promising LC-MS assay for preeclampsia risk assessment. Poster session presented at MSACL, Salzburg, Austria. |
Lenaerts, C., Deplechin, T., & Blankert, B. (22 June 2014). Set up of a solid phase extraction (SPE) method of marinobufagenin from human plasma. Poster session presented at Drug Analysis, Liège, Belgium. |
Lenaerts, C., Deplechin, T., & Blankert, B. (13 February 2014). Purification and extraction of marinobufagenin from Bufo Marinus toad venom and from human plasma. Poster session presented at 6ème Journée Scientifique du Pôle hainuyer, Mons, Belgium. |
| Lenaerts, C., Demeyer, M., Gerbaux, P., & Blankert, B. (17 October 2013). Challenges and novel strategies for quantification of marinobufagenin within the framework of preeclampsia. Paper presented at 17th Forum of Pharmaceutical Sciences, Spa, Belgium. |
| Lenaerts, C., Larcy, C., & Blankert, B. (13 June 2013). Analytical aspects of marinobufagenin and its applications in the diagnosis of preeclampsia. Poster session presented at ISSHP (International Society of the Study of Hypertension in Pregnancy) European Congress, Tromso, Norway. |
Lenaerts, C., Larcy, C., & Blankert, B. (01 June 2013). Analytical aspects of marinobufagenin and its applications in the diagnosis of preeclampsia. Pregnancy Hypertension, 3, 99. Peer reviewed |
 | Lenaerts, C., & Blankert, B. (24 May 2013). Marinobufagenin : a new diagnosis target for preeclampsia syndrome? Poster session presented at 1st Health Institute Day, Mons, Belgium. |
Lenaerts, C., & Blankert, B. (12 March 2013). Marinobufagenin: a new diagnostic target for preeclampsia syndrome? Poster session presented at 7ème édition de la Matinée de Chercheurs, Mons, Belgium. |
Lenaerts, C., Helvenstein, M., & Blankert, B. (29 January 2013). Marinobufagenin and its applications in the diagnosis of preeclampsia. Poster session presented at Journée scientifique des doctorants en Sciences Biomédicales et Pharmaceutiques: 'New tools and strategies in identification of pathology-related biomarkers', UMONS, Belgium. |
| Lenaerts, C., Demeyer, M., Gerbaux, P., & Blankert, B. (01 January 2013). Analytical aspects of marinobufagenin. Clinica Chimica Acta, 421, 193-201. Peer Reviewed verified by ORBi |
| Lenaerts, C., & Blankert, B. (16 October 2012). Analytical aspects of marinobufagenin and its applications in the diagnostic of preeclampsia. Paper presented at VIIe PhD Day de l'école doctorale en sciences pharmaceutiques ULB/UMONS, Bruxelles, Belgium. |